BELVIQ NEWS ITEMS - BELVIQ DANGERS - CANCER, SAFETY AND SIDE EFFECTS
January 14th, 2020 – Belviq, Belviq XR (lorcaserin): Drug Safety Communication – Due to Possible Increased Risk of Cancer
January 15th, 2020 – FDA Issues Cancer Warning Over Weight-Loss Drug Belviq. The Food and Drug Administration (FDA) has warned the weight-loss drug Belviq, and its once-daily formulation Belviq XR, carry a possible increased risk of cancer.
January 16th, 2020 – The prescription weight control medicine lorcaserin (Belviq, Belviq XR) may increase the risk of cancer, according to the results of a clinical trial assessing the safety of the drug, the U.S. Food and Drug Administration says.
February 13th, 2020 – Belviq, Belviq XR (lorcaserin) by Eisai: Drug Safety Communication – FDA Requests Withdrawal of Weight-Loss Drug
February 13th, 2020 – Drugmaker Eisai to withdraw weight loss drug Belviq after trials find cancer link
February 13th, 2020 – The weight management medicine Belviq (chemical name: lorcaserin), also available as Belviq XR, seems to be linked to an increase in cancer risk, according to an announcement on Jan. 14, 2020, by the U.S. Food and Drug Administration (FDA).
February 13th, 2020 – Lorcaserin Pulled From Market Following FDA Cancer Warning. After the US Food and Drug Administration (FDA) issued a Drug Safety Communication concerning their weight-loss add-on lorcaserin (BELVIQ, BELVIQ XR), Eisai Inc. announced they were removing the treatment and lorcaserin would no longer be sold in the US market.
February 13th, 2020 – Weight Loss Drug Belviq Being Taken Off Shelves Due to Cancer Concerns . The Food and Drug Administration (FDA) and the manufacturer of the weight loss medication Belviq and Belviq XR have agreed to a voluntary withdrawal of the drugs after research indicated the drugs could raise the risk of several types of cancer.
February 14th, 2020 – FDA: Obesity Drug Lorcaserin Exits US Market Over Cancer Concerns
February 14th, 2020 – Weight Loss Drug Belviq Pulled From Market After FDA Identifies Potential Cancer Risk. Eisai Inc., the maker of Belviq and Belviq XR (lorcaserin) said in a February 13, 2020, statement that it is voluntarily withdrawing the drugs.
February 17th, 2020 – FDA requests market withdrawal of weight-loss drug Belviq. After clinical trials showed an increased risk of cancer in patients taking Belviq, the FDA has recommended the withdrawal of the drug from the US market.
February 17th, 2020 –Weight Loss Drug Belviq Found to Increase Cancer Risk, Pulled from Shelves. The Food and Drug Administration (FDA) requested that weight loss drug lorcaserin (Belviq) be withdrawn from the shelves after clinical trial data suggested that it increased the risk of cancer.
February 20th, 2020 – Based on a recently completed analysis of data from the CAMELLIA-TIMI 61 trial, Eisai, the manufacturer of Belviq (lorcaserin HCl) and Belviq XR (lorcaserin HCl extended-release), has decided to withdraw both weight-loss agents from the market.
February 20th, 2020 – Obesity is a chronic health condition that affects more than one in three Americans. Some individuals struggling with weight issues might not get benefited from regular physical activity and a healthy eating plan alone and their doctors might prescribe medications as part of their weight-control program. The U.S. FDA had approved orlistat (Xenical, Alli), lorcaserin (Belviq), phentermine-topiramate (Qsymia), naltrexone-bupropion (Contrave), and liraglutide (Saxenda) for long-term use. But, following the results of a recent safety trial, the FDA has issued a warning that lorcaserin (Belviq) might increase one’s risk of cancer. Read more.
April 9, 2020 – In February, the manufacturer of the weight-loss medication lorcaserin (Belviq, Belviq XR) voluntarily withdrew the drug from the US market at the request of the FDA. This was a result of emerging data showing that people who had taken the drug as part of a large clinical trial had an increased occurrence of cancer five years later. Read more.
We’re filing lawsuits against the manufacturer of Belviq for failing to properly study and evaluate Belviq and providing misleading information about the safety of the diet pill. Please contact our attorneys today!